Tirzepatide
- Generic Name
- Tirzepatide
- Brand Names
- Mounjaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2023788-19-2
- Unique Ingredient Identifier
- OYN3CCI6QE
- Background
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclini...
- Indication
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Drugmakers say obesity medicine shortages are easing, but patients struggle to fill prescriptions
Patients struggle to get obesity and diabetes drugs like Wegovy and Mounjaro due to high demand and supply shortages. Drugmakers Novo Nordisk and Eli Lilly report availability but patients still face difficulties. The FDA monitors the situation, and drug companies are expanding production. Signs of easing shortages include the return of pharmaceutical samples to doctors' offices.
Obesity Drugs Will Get Broad Commercial Coverage In 2025 Despite Cost Concerns, Survey Says
Most large employers plan to cover GLP-1 drugs for obesity in 2025, despite cost concerns. Employers anticipate increased spending on GLP-1 drugs, with 40% planning to cover them for cardiovascular conditions in 2025. Employers use prior authorization and weight management programs to manage costs.
This Big Move by Eli Lilly May Solve the Weight Loss Drug Market's Biggest Problem
Eli Lilly launched a new version of Zepbound in single-dose vials to address supply issues, priced at $399 and $549 for four-week supplies. This move aims to boost revenue in the expanding weight loss drug market, which could reach $100 billion by the end of the decade.
Eli Lilly says experimental insulin could mean 313 fewer injections per year
Eli Lilly's weekly insulin efsitora shows similar efficacy to daily insulin in type 2 diabetes patients, potentially reducing injection frequency from daily to weekly.
Weight Loss Drug Reduces Diabetes Risk by 94 Percent in Clinical Trial
Tirzepatide, in Zepbound, reduced type 2 diabetes risk by 94% in obese or overweight adults with pre-diabetes, with sustained weight loss. Potential side effects include stomach and kidney issues, low blood sugar, and allergic reactions. Long-term effectiveness remains uncertain.
Weight-Loss Drug Zepbound Now in Single-Dose Vials at Half the Price
Eli Lilly introduces single-dose vials of weight-loss drug Zepbound at half the price, available via LillyDirect, aiming to widen access and prevent unsafe copycat versions.
Tirzepatide Reduced the Risk of Developing Type 2 Diabetes by 94% in Adults with Pre-Diabetes and Obesity or Overweight
Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight, and resulted in sustained weight loss over a three-year treatment period.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath